– New AI Module Offers ‘Target-to-T Cell’ Approach Revolutionizing Target Identification and Prioritization in a Personalized Antigen Approach –
LONDON, May 10, 2023 (Globe Newswire) — A clinical-stage biopharmaceutical company developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors Achilles Therapeutics plc (NASDAQ: ACHL) today announced that the company’s new AI-trained application, which was trained on proprietary real-world data, is the current AI and non-AI state-of-the-art for neoantigen immunogenicity prediction in a recent analysis. methods, allowing the identification of the most potent clonal neoantigens for personalized cancer therapy. Details of this new capability of his AI-powered PELEUS™ bioinformatics platform will be presented at an upcoming academic conference.
Of the large number of neoantigens initially identified in patient tumors, only a few elicit T-cell responses that can provide clinical benefit. Achilles has developed an AI tool that allows the prospective identification of the most potent neoantigens. The new PELEUS™ neoantigen immunogenicity ranking module was trained and validated using data from over 10,000 neoantigens, from in silico identification to expansion and characterization of real his T cell clones. Using this new tool, the PELEUS™ platform will be able to accurately predict which neoantigens are most likely to generate potent T-cell responses, helping our ongoing TIL against advanced non-small cell lung cancer. It supports the potential implementation of the platform into base clinical programs (NSCLC) and melanoma, as well as other therapeutic modalities such as clonal neoantigen cancer vaccines.
“Our ‘Target-to-T Cell’ approach offers a range of precision therapeutic approaches, from our proprietary T-cell approach with TIL-based clonal neoantigen-reactive T cells (cNeT) to a personalized neoantigen approach. We believe that the key to accurate predictions and thus the best neoantigens and related products is to train AI systems on the highest quality datasets. said Dr. Sergio Quezada, Chief Scientific Officer, Achilles Therapeutics. “The superiority of our patent-protected PELEUS™ platform in predicting clinically relevant clonal neoantigens using this new AI module has transformative potential. A focus on should promote long-lasting and durable responses with a wide range of precision therapies.”
Analysis conducted by the Bioinformatics & Data Science team at Achilles found that the PELEUS™ platform outperformed ranking performance compared to currently used state-of-the-art methods as measured by the “Area Under the Receiver Operating Characteristic Curve” (ROC). It has been proven to improve significantly. AUC). ROC AUC evaluates the performance of machine learning models to predict in vivo confirmed neoantigens. The PELEUS™ AI Immunogenicity Ranking Tool was derived from patient material from the Achilles Material Acquisition Program (MAP), the ongoing CHIRON trial in patients with advanced NSCLC, and the THETIS trial in relapsed or metastatic patients. Developed and trained using our own real-world data. melanoma. Current AI methods are trained on publicly available data from sources such as the Immune Epitope Database (IEDB), a freely available resource funded by the National Institute of Allergy and Infectious Diseases (NIAID). increase.
About Achilles Therapeutics
Achilles is a clinical-stage biopharmaceutical company developing AI-powered precision T-cell therapies targeting clonal neoantigens, individual protein markers expressed on the surface of all cancer cells. The company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequence data from each patient and his unique PELEUS™ bioinformatics platform to identify clonal his neoantigens unique to that patient, and to specifically target those clonal neoantigens. Developing his T cell-based product candidates with precision.
About Peleus
PELEUS is a unique AI-powered bioinformatics platform built and validated through exclusive access to TRACERx know-how and genomics data. PELEUS uses advanced Bayesian statistical algorithms to identify which mutations or neoantigens within a patient’s tumor are clonal or subclonal by analyzing DNA sequence information from multiple tumor regions. increase. Clonal neoantigens are protein markers present in all cancer cells in an individual but absent in healthy tissues, making them ideal targets for cancer. Information from PELEUS provides the basis for Achilles’ VELOS manufacturing process that produces clonal neoantigen-reactive T cells (cNeT).
About TRACERx
Led by Professor Charles Swanton at UCL, TRACERx (Tracking Cancer Evolution by Therapy (Rx)) will generate deep sequencing multi-region and multi-time genetic data from over 3,200 tumor samples from approximately 800 tumor samples It is one of the largest tumor evolution studies to date. lung cancer patient. TRACERx has changed our understanding of tumor evolution, convincingly showing that tumors arise from single cells that evolve in a Darwinian manner, with early (clonal) mutations conserved in all subsequent primary and metastatic tumor cells. I was. This work has spawned numerous publications and has highlighted the importance of cancer evolution and immune evasion by analyzing the genetic signature of lung tumors and tracking how it evolves over time from diagnosis to relapse. revealed a mechanism. These findings provide the ability to identify a new class of tumor markers, called clonal neoantigens, that are present in all tumor cells but not in healthy tissues, making them ideal cancer targets. TRACERx represents Cancer Research UK’s largest investment in lung cancer research, with Achilles having exclusive commercial rights to his TRACERx research data for the development of neoantigen-targeted cell therapies and vaccines .
Forward-Looking Statements
This press release contains forward-looking statements, expressed or implied, that are based on the beliefs and assumptions of our management and information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events and our future operating or financial performance and Actual results or performance or results that differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. Subsequent events and developments are expected to change our views. However, while we may choose to update these forward-looking statements at some point in the future, we do not currently intend to do so, except to the extent required by applicable law. Accordingly, these forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Investor:
Mel Advisors
Lee M. Stern
ir@achillestx.com
media:
Strategic Communication of Concilium
Mary-Jane Elliott, Skyna Verge, Melissa Gardiner
+44 (0) 203 709 5000
achillestx@consilium-comms.com
© OMX, Source GlobeNewswire – EU Press Release
